Core Activities of IVI
IVI research falls into one or more of several core areas related to our mission and goal.
Every individual and organization who interacts with the U.S. health care system has a stake in how we assess the value of health care interventions. Traditional approaches that provide little transparency, limited perspective, and static evidence fail to meet the diverse and evolving needs for information among these stakeholders. IVI is redefining how value is assessed by pioneering an open-source and consensus-driven process for building flexible value assessment model platforms.
Every day, countless decision-makers weigh the relative value of treatment options for patients. Patients and providers make choices about treatment strategies. Insurers make formulary and coverage decisions. Hospital systems decide how to allocate their resources to ensure access for critically ill patients. Employers struggle to contain growing health care budgets. And the list goes on. IVI provides these diverse stakeholder groups with innovative tools to determine the value of alternative treatments, based on patients’ specific clinical circumstances, preferences, and insurance arrangements.
To accurately and comprehensively measure value, new methods are needed that capture hard-to-measure costs and benefits and incorporate the perspectives of multiple stakeholders. IVI conducts research that develops state-of-the-art methods for measuring the value of new medical technologies. IVI also supports initiatives that educate and advise practitioners, health care system stakeholders, and policymakers about these methods to ensure they become a part of standard practice.
Frequently, public policy discussion focuses on the symptoms instead of the underlying issues in our health care system. IVI’s research adds balanced and objective insights to the policy debate. IVI conducts and disseminates policy analysis to educate the public and policy makers about the short- and long-term consequences of policies affecting pricing, access, innovation, and patient health and examines costs and benefits of potential policy reforms that can better ensure increased access to high-value treatments and limit the use of low-value treatments.
Nearly unprecedented consensus has emerged over the need to align reimbursement and utilization with value… [but] we cannot reward value until we properly measure it.
Quantifying the Patient Experience: Developing Patient-Centered QALYs in Cancer
Accurately capturing the experienced benefits and costs to patients is one of the most important challenges in value assessment – and it is crucial to understanding value. As a step toward developing improved measures that capture the diverse treatment experiences of patients, IVI is developing QALY measures tailored specifically to patients in treatment for a single disease: non-small cell lung cancer (NSCLC).
Expanding Cost-Effectiveness Analysis (CEA) to All of Health Care: Comparisons Between CEAs on Pharmaceuticals and Medical/Surgical Procedures
Cost-effectiveness analysis has been applied extensively for pharmaceuticals, but less so for medical and surgical goods and services, we evaluate similarities and differences between characteristics of pharmaceutical CEA studies and CEA studies of medical or surgical procedures, and examine potential policy solutions to achieve a more balanced mix of CEAs across interventions and ultimately help us better diagnose and treat patients.
Patient Insights on Value in Rheumatoid Arthritis
IVI worked with focus groups to explore patient’s perspectives on care for rheumatoid arthritis (RA) and learn how RA patients deliberate their treatment options. The specific objectives of the focus groups were to 1) identify attributes of treatment that RA patients prefer or prioritize as most important in their treatment decisions, and 2) elicit recommendations for, and assess the utility of, a web tool to facilitate decision-making about RA treatment. Findings outlined in the IVI report are based on focus groups conducted in January 2017 with RA patients residing in the Atlanta, Georgia metropolitan area.